HHS Awards Over $2B For Manufacturing Of COVID-19 Drug, Vaccine

Novavax will receive $1.6 billion from HHS to make its COVID-19 vaccine candidate, and Regeneron Pharmaceuticals will receive $450 million to scale up production of its antibody candidate, HHS announced on Tuesday (June 7). The Novavax contract is the largest Operation Warp Speed award so far, and the Regeneron contract marks the first time the Trump administration is directly buying a COVID-19 drug. Manufacturing of both products will take place while the products are being tested in clinical trials so...